Workflow
GOLDSTONE ASIA PHARM.(300434)
icon
Search documents
金石亚药(300434) - 2024年年度股东大会决议公告
2025-05-23 10:14
2024 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 特别提示: 1、本次股东大会未出现否决议案的情形; 2、本次股东大会未涉及变更以往股东大会已通过的决议。 证券代码:300434 证券简称:金石亚药 公告编号:2025-020 四川金石亚洲医药股份有限公司 2、现场会议召开地点:杭州市滨江区江南大道 4760 号亚科中心公司会议室 3、会议召开方式:本次股东大会采取现场投票和网络投票相结合的方式 4、会议召集人:公司第五届董事会 5、会议主持人:公司董事长马益平先生 6、会议召开的合法、合规性:2025 年 4 月 23 日,公司第五届董事会第八 次会议审议通过《关于召开 2024 年年度股东大会的议案》,决议召开本次股东大 会,本次股东大会会议召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定。 (二)会议的出席情况 1、会议召开的时间 (1)现场会议召开时间:2025 年 5 月 23 日(星期五)下午 2:00 (2)网络投票时间:通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 23 ...
金石亚药(300434) - 2025年5月16日投资者关系活动记录表
2025-05-16 09:36
Group 1: Company Strategy and Development - The company adheres to a dual strategy of independent and collaborative research and development, enhancing its long-term development through strategic investments and internal resource integration [1] - The company aims to become a trusted and preferred provider of professional healthcare products, focusing on a unified operational system across R&D, marketing, and production [2] - The company plans to implement a four-pronged growth model encompassing OTC, prescription drugs, traditional Chinese medicine, and health products to support high-quality development [2] Group 2: Marketing and Sales Achievements - The company has established a comprehensive marketing system, covering over 3,000 chain pharmacies and approximately 240,000 cooperative chain stores, reaching over 90% of cities and 70% of districts nationwide [2] - The company’s online channel strategy includes partnerships with e-commerce platforms to enhance product accessibility and consumer engagement [2] Group 3: Financial Performance - In 2024, the pharmaceutical segment generated revenue of 915 million yuan, accounting for 82.96% of total revenue, with the "Kuaike" series contributing 612 million yuan, representing 55.49% of total revenue [3] - The company’s cold and flu medications account for approximately 56% of total revenue [4] Group 4: Product Development and Market Position - The "Kuaike" cold medicine has ranked first in the annual comprehensive statistics of non-prescription drugs in China for three consecutive years from 2021 to 2023 [3] - The company has successfully launched the "Kuaike Qing" oseltamivir capsules and has received re-listing permits for other products [1] Group 5: Future Plans and Challenges - The company is actively preparing for the flu season by optimizing production capacity and ensuring smooth supply channels [5] - The company is exploring opportunities in traditional Chinese medicine, developing high-quality products to enhance market share in this sector [5]
化学制药板块震荡拉升,亨迪药业涨超10%
news flash· 2025-05-16 01:54
Group 1 - The chemical pharmaceutical sector experienced a significant rally, with Hendi Pharmaceutical (301211) rising over 10% [1] - Xinhua Pharmaceutical (000756) reached its daily limit up [1] - Other companies such as Jinshi Yiyao (300434), Haichuang Pharmaceutical, and Duori Pharmaceutical (301075) also saw increases [1]
金石亚药2024年净利润大降27% “快克”系列收入下滑
Xi Niu Cai Jing· 2025-05-09 02:37
Financial Performance - In 2024, the company achieved operating revenue of 1.102 billion yuan, a year-on-year decrease of 8.84% [5] - The net profit attributable to shareholders was 91.76 million yuan, down 27.29% year-on-year [5] - The basic earnings per share were 0.23 yuan per share [5] Key Financial Ratios - The net cash inflow from operating activities was 158 million yuan, an increase of 4.6% year-on-year [4] - The weighted average return on equity was 3.75%, a decrease of 1.65 percentage points year-on-year [4] - The gross profit margin was 57.44%, down 6.44% year-on-year [4] - The asset-liability ratio stood at 19.16%, and the net profit margin was 8.03% [4] Business Segment Performance - The core product "Kuaike" series in the cold medicine segment accounted for 55.49% of revenue but saw a year-on-year decline of 17.16% due to shrinking retail demand and competition from foreign products [4] - Revenue from health food and traditional Chinese medicine slices was 39.09 million yuan, down 7.98% year-on-year, with the new product "Jinxing Glucosamine Soft Capsule" not yet achieving scale [4] - Revenue from complete production lines was 147 million yuan, marking a significant year-on-year increase of 89.95% [4] Research and Development - In 2024, the company's R&D investment was 49.99 million yuan, accounting for 4.54% of revenue [6] - The consistency evaluation for Diclofenac Sodium Sustained-Release Tablets has entered the application stage, and the antiviral drug Oseltamivir Phosphate Capsules have been approved for market [6] - The company plans to accelerate the promotion of "Jinxing Glucosamine Soft Capsule" through e-commerce channels [6] Dividend Distribution - The company plans to distribute a cash dividend of 0.69 yuan per 10 shares (including tax) in 2024 [7] International Expansion - The mechanical segment is providing customized magnetron sputtering vacuum coating equipment to global clients, with a factory planned in Mexico to enhance hydrogen pipeline technology output capabilities [6]
21健讯Daily | 七部门:开展“人工智能赋能医药全产业链”应用试点;万泰生物第一季度净亏损5277.69万元
Policy Developments - Seven departments, including the Ministry of Industry and Information Technology, issued the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)", emphasizing the integration of artificial intelligence across the pharmaceutical supply chain [1] Drug and Device Approvals - Kangtai Biological announced that its subsidiary Minhai Biological's application for the marketing authorization of an adsorbed tetanus vaccine has been accepted by the National Medical Products Administration [2] - Hendi Pharmaceutical received approval for the marketing application of arginine ibuprofen, a non-steroidal anti-inflammatory drug with superior solubility and faster absorption compared to regular ibuprofen [3] - Tianyao Pharmaceutical's subsidiary obtained a drug registration certificate for injectable hydrocortisone sodium succinate, used for critical conditions such as allergic shock and severe adrenal insufficiency [4] Financial Reports - Wantai Biological reported a net loss of 52.78 million yuan in Q1 2025, with revenue of 401 million yuan, a year-on-year decline of 46.76%, primarily due to market adjustments and government procurement impacts [5] - Heng Rui Pharmaceutical's Q1 2025 report showed a revenue of 7.206 billion yuan, a year-on-year increase of 20.14%, and a net profit of 1.874 billion yuan, up 36.9%, largely due to a licensing payment from IDEAYA [6] - Kingstone Pharma reported a revenue of 291 million yuan in Q1 2025, down 19.65%, with a net profit of 62.85 million yuan, a decrease of 30.02% [8] - Baijun Medical achieved a revenue of 100 million yuan in Q1 2025, a 31.3% increase, with a net profit of 32.50 million yuan, up 290.69%, driven by stable sales of existing products and successful new product launches [9] Capital Market Activities - Tonghe Pharmaceutical plans to invest 11 million yuan to increase its stake in Hangzhou Boya Biomedical Co., Ltd., raising its ownership from 16.34% to 24.93% [10] - Chengyuan Biotechnology announced the completion of several million yuan in equity financing, aimed at upgrading its gene synthesis technology platform [11] Industry Developments - Zhang Wenhong's team announced significant progress in developing a broad-spectrum antiviral drug for monkeypox, which is set to enter clinical approval stages [12] - Qianxin Biotechnology signed a licensing agreement with Caldera Therapeutics for its long-acting dual antibody QX030N, granting global exclusive rights for development and commercialization [13] Public Sentiment Alerts - Weiming Pharmaceutical announced that its important subsidiary, Tianjin Weiming, was suspended from production and sales, which could trigger further risk warnings if production does not resume within three months [14]
金石亚药财报“告急”:连续两期净利下滑三成左右,核心产品感冒药市场“退烧”致业绩 不彰
Shen Zhen Shang Bao· 2025-04-24 15:19
深圳商报·读创客户端记者 穆砚 2024年全年,金石亚药营收与净利润延续下滑趋势,其中净利润同比降幅达27.29%,这一颓势延续至 2025年第一季度。公司核心产品"快克"感冒药系列曾因特殊时期需求激增拉动业绩增长,但随着市场回 归常态,消费者囤货逐步消化,叠加2024年流感季患者转向院内治疗比例增加,零售端感冒药销售明显 萎缩。 从业务结构看,金石亚药对感冒药单一品类的依赖加剧了业绩波动。尽管公司近年尝试拓展保健品和处 方药业务,但新业务贡献尚未形成规模。从行业情况方面看,据记者了解,随着医药行业政策调整,外 资产药品加速进入国内市场,仿制药一致性评价持续推进,进一步挤压中游药企生存空间。 金石亚药在年报中提示,公司主营业务为非处方药品、处方药品、原料药和保健食品的研发、生产及销 售,目前拥有90余个药品生产批准文号,并拥有7个保健食品生产批准文号,其中5个为注册类。报告期 内,快克感冒药系列(复方氨酚烷胺胶囊、小儿氨酚黄那敏颗粒)产品销售收入占公司各期营业收入、销 售毛利额占公司各期主营业务毛利额的比例都比较高,为公司主营业务收入及盈利的主要来源。公司的 主导产品较为集中,在相应的细分市场中具有较为明显的 ...
金石亚药(300434) - 关于聘任证券事务代表的公告
2025-04-24 10:24
证券代码:300434 证券简称:金石亚药 公告编号:2025-016 四川金石亚洲医药股份有限公司 关于聘任证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 四川金石亚洲医药股份有限公司(以下简称"公司")于 2025 年 4 月 23 日召开第五届董事会第八次会议,审议通过了《关于聘任证券事务代表的议案》。 同意聘任易盛兰女士(简历附后)为公司证券事务代表,与公司证券事务代表王 莹女士共同协助董事会秘书履行职责,任期与公司本届董事会任期一致。 易盛兰女士已取得深圳证券交易所董事会秘书资格证书,具备与其行使职权 相应的任职条件,不存在《深圳证券交易所创业板股票上市规则》、《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》规定的不得 担任上市公司证券事务代表的情形。 公司证券事务代表易盛兰女士联系方式如下: 传 真:028-85628208 电子信箱:goldstone@gsap-group.com 特此公告。 附件:易盛兰女士简历 四川金石亚洲医药股份有限公司 董 事 会 二〇二五年四月二十五日 联系人:易盛兰 联 ...
金石亚药(300434) - 2024年度监事会工作报告
2025-04-24 10:24
四川金石亚洲医药股份有限公司 2024 年度监事会工作报告 2024 年,四川金石亚洲医药股份有限公司(以下简称"公司")监事会, 严格依照《公司法》、《证券法》等法律法规,以及《公司章程》、《监事会议事 规则》的有关规定认真履行监督职责,依法独立行使职权,对公司的生产经营、 重大事项、财务状况、内部控制、信息披露、关联交易以及董事、高级管理人 员履行职责等方面进行了有效的审查和监督,切实维护公司和股东的合法权益。 现将 2024 年度监事会主要工作汇报如下: (二)检查财务和定期报告审核情况 报告期内,监事会定期对公司的财务状况和财务制度等进行监督和检查。 监事会认为:公司财务制度健全,财务体系运作规范,财务状况良好,不存在 控股股东及关联方非经营性资金占用或违规对外担保的情况;公司编制的财务 报表能够客观反映公司的财务状况和经营成果,定期报告内容真实、准确、完 整,不存在任何虚假记载、误导性陈述或者重大遗漏。立信会计师事务所(特 殊普通合伙)出具的审计报告真实、公允地反映了公司 2024 年度的财务状况和 经营成果,对审计报告无异议。 (三)公司内部控制情况 一、 2024 年度监事会工作情况 报告期内, ...
金石亚药(300434) - 2024年度财务决算报告
2025-04-24 10:24
四川金石亚洲医药股份有限公司 2024 年度财务决算报告 一、年度财务报告及审计情况 公司聘请立信会计师事务所(特殊普通合伙)审计公司及其子公司的 2024 年度财务报表, 包括 2024 年 12 月 31 日的资产负债表和合并资产负债表、2024 年度的利润表和合并利润表,2024 年度现金流量表和合并现金流量表,以及财务报表附注。立信会计师事务所(特殊普通合伙)对 上述审计范围内的公司均出具了标准无保留意见的审计报告。 如无特殊说明,下述描述和数据均为合并口径,单位:人民币元。 二、2024 年度公司主要财务指标 | 项 目 | 2024 年 | 2023 年 | 本年比上年增减 | | --- | --- | --- | --- | | 营业收入(元) | 1,102,354,866.43 | 1,209,199,438.06 | -8.84% | | 归属于上市公司股东的净利润(元) | 91,761,833.80 | 126,199,723.64 | -27.29% | | 归属于上市公司股东的扣除非经常性损益的净利润 | 82,294,435.98 | 114,113,258.00 | -27. ...